Horizon doses first participant in Phase I gout therapy trial

The Phase I trial will evaluate the pharmacokinetics, tolerability, pharmacodynamics, and safety of HZN-457.

The Metaverse: Macroeconomic trends

Gaming and social media companies are at the vanguard of metaverse development, but enterprises will lead the charge in the…

Biosimilars hit a turning point as they expand outside oncology

Biosimilar drugs are biological medicines that are extremely similar to another biological medicine that has already been licensed for use.

Health Canada grants CTA authorisation for QurAlis’ ALS therapy

Assessing the safety and tolerability of varying doses of QRL-201 in ALS patients is the primary objective of the trial.

Leading artificial intelligence (AI) companies in clinical trials

Artificial intelligence (AI) is instrumental in solving several key clinical trial challenges. It can help in the synthesis and analysis…